Heikki Joensuu
MD, PhD
Professor, Department of Oncology
👥Biography 个人简介
Dr. Heikki Joensuu is renowned for developing risk stratification criteria widely used in GIST (the Joensuu modified classification) and for leading the SSGXVIII/AIO trial demonstrating that 3 years of adjuvant imatinib is superior to 1 year in high-risk GIST, which established the current standard of care for adjuvant therapy. His contributions have directly impacted patient survival in resected GIST.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Heikki Joensuu 的研究动态
Follow Heikki Joensuu's research updates
留下邮箱，当我们发布与 Heikki Joensuu（Helsinki University Central Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment